Return to Article Details
Comparative Risk of Metabolic Adverse Outcomes in Patients with Schizophrenia Spectrum Disorder Treated with Aripiprazole Versus Olanzapine: A Retrospective Cohort Study Using the Global TriNetX Network
Download PDF